About Imutex

Imutex Limited is a joint venture between PepTcell (51%) and hVIVO plc (49%).

The Imutex vaccines have been designed to provide a broadly protective immune response against disease through viral clearance by cytotoxic T cells secreting pro-inflammatory cytokines and cytotoxic molecules such as granzyme B.

The vaccines have been designed using ConserV Bioscience’s (a spinoff of PepTcell) proprietary in silico platform which can accurately predict reactive versus non-reactive binding epitopes

Imutex’s has currently two vaccines in clinical development: Flu-V, a phase 3 ready universal flu vaccine and AGS-v Plus, a vaccine against Mosquito Borne Diseases with positive Phase 1 data from two NIH-sponsored studies.